Severe Acne Vulgaris - Pipeline Insight, 2024

Severe Acne Vulgaris - Pipeline Insight, 2024

DelveInsight’s, “Severe Acne Vulgaris - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Acne Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Severe Acne Vulgaris Understanding

Severe Acne Vulgaris: Overview

Acne vulgaris (commonly referred to as acne) is a common skin disease in which hair follicles become clogged with dead skin and oils resulting in inflammation. Acne has a varied etiology which includes genetics, hormonal function, bacterial growth, and other causes. Clinically, ance can be identified by open or closed comedones, and/or by erythematous papules and pustules on the face, as well as erythema on the surrounding skin. Likewise, acneiform scarring may also occur which may or may not present with comedones. The diagnosis of acne is based on the history and physical examination. Lesions most commonly develop in areas with the greatest concentration of sebaceous glands, which include the face, neck, chest, upper arms, and back. Acne may be triggered or worsened by external factors such as mechanical obstruction (i.e., helmets, shirt collars), occupational exposures, or medications. Common medications that may cause or affect acne are listed in Table 1.4 Cosmetics and emollients may occlude follicles and cause an acneiform eruption. Topical corticosteroids may produce perioral dermatitis, a localized erythematous papular or pustular eruption.

""Severe Acne Vulgaris - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Acne Vulgaris pipeline landscape is provided which includes the disease overview and Severe Acne Vulgaris treatment guidelines. The assessment part of the report embraces, in depth Severe Acne Vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Severe Acne Vulgaris.
• In the coming years, the Severe Acne Vulgaris market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Severe Acne Vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Severe Acne Vulgaris treatment market. Several potential therapies for Severe Acne Vulgaris are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Severe Acne Vulgaris market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Severe Acne Vulgaris) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Severe Acne Vulgaris Emerging Drugs Chapters

This segment of the Severe Acne Vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Severe Acne Vulgaris Emerging Drugs

• ASC40: Ascletis Pharmaceuticals

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis. Human sebum production requires de novo lipogenesis, which is increased in acne and suppressed by the FASN inhibitor ASC40. Currently, it is in Phase II stage of clinical trial evaluation to treat Moderate to Severe Acne Vulgaris.

• BPX-01: BIOPHARMX

BioPharmX is developing a novel, proprietary topical minocycline gel formulation (BPX-01) for the treatment of acne vulgaris. The product is the first candidate from our anhydrous hydrophilic topical delivery system and in our formulation, the minocycline is completely solubilized. The formulation is currently in clinical development for patients with inflammatory lesions of acne vulgaris. BPX-01 utilizes minocycline that is solubilized and stable in a vehicle that is hydrophilic and capable of penetrating into the region of the skin where P. acnes reside. Compared to lipophilic ointments and suspensions, which can be oily to the touch and leave residue, the hydrophilic BPX-01 is rapidly absorbed into the skin rather than remaining on the surface and has many benefits such as high bioavailability, ease of application, non-irritating and non-fluorescing. BioPharmX scientists have conducted extensive in vitro and in vivo studies demonstrating selective delivery of minocycline to the epidermis and the pilosebaceous unit. In a phase 2a clinical study, BPX-01 demonstrated a statistically significant reduction in facial P. acnes after four weeks of once-daily treatment with no measurable systemic levels of minocycline and no drug-related adverse effects. Based on these observations and the promising preclinical data, the company conducted a phase 2b dose-ranging study to evaluate the safety and efficacy of two different concentrations of BPX-01 compared to vehicle in patients with moderate-to-severe acne.

Further product details are provided in the report……..

Severe Acne Vulgaris: Therapeutic Assessment

This segment of the report provides insights about the different Severe Acne Vulgaris drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Severe Acne Vulgaris

There are approx. 10+ key companies which are developing the therapies for Severe Acne Vulgaris. The companies which have their Severe Acne Vulgaris drug candidates in the most advanced stage, i.e. phase II include, BIOPHARMX.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Severe Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Severe Acne Vulgaris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Acne Vulgaris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Acne Vulgaris drugs.

Severe Acne Vulgaris Report Insights

• Severe Acne Vulgaris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Severe Acne Vulgaris Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Severe Acne Vulgaris drugs?
• How many Severe Acne Vulgaris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Severe Acne Vulgaris?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Severe Acne Vulgaris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Severe Acne Vulgaris and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ascletis Pharmaceuticals
• BioPharmX Corporation
• Biofrontera
• Boston Pharmaceuticals
• Botanix Pharmaceuticals
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
• Vyne Therapeutics Inc.
• DERMATA THERAPEUTICS
• Novan

Key Products

• ASC40
• BPX-01
• BF-200
• BOS-356
• BTX 1503
• Aminolevulinic acid
• FCD105
• DMT310
• VB-1953
• SB 204